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ABSTRACT 
BACKGROUND 
 Oral cancer is one of  the leading causes of cancer death in India.  
Due to persistence or recurrence of cancer despite aggressive therapy,  
there is a necessity for the need of treatment modalities that  can target 
the molecules in the signaling pathway that  are activated in canc er 
conditions. The Mammalian Target of Rapamycin (mTOR) is a member 
of the Phosphatidyl inositol 3 (PI- 3)- Kinase-family & downstream 
molecule in the Akt /mTOR/pS6 signaling pathway which plays a 
cri tical role in regulating basic cellular functions includi ng cell 
proliferation, cell survival, motility and angiogenesis. In carcinoma 
conditions, there will be dysregulation in the Akt /mTOR/pS6 signaling 
pathway. Hence, our present study is conducted to find the expression 
of p-mTOR in different grades of Oral  Squamous Cell Carcinoma and 
to compare it with normal mucosa.  
 
AIM: 
 The aim of this study is to analyse the Immunohistochemical 
expression of phosphorylated form of mTOR in different grades of 
OSCC in comparison with normal mucosa . 
 
MATERIALS & METHODS: 
 This study was conducted on the archival retrieved formalin 
fixed, paraffin embedded tissues obtained from the Department of Oral 
Pathology, Adhiparasakthi Dental  College and Hospital, 
Melmaruvathur and from private hospitals. The study group included 
21 cases of histologically diagnosed Oral Squamous Cell Carcinoma (7 
cases of each Well,  Moderately and Poorly differentiated squamous cell 
carcinoma).  Control  group includes biopsies from the normal buccal 
mucosa adjacent to the site of surgery during the su rgical removal of 
third molar in 10 patients. 3 micron thickness sections were made from 
each sample and stained with p -mTOR primary antibody. The 
expression was scored and analysed using Kruskal Wallis test .  
 
RESULTS: 
 Statist ically significant difference  (p=0.03) exists when 
comparing the intensity of staining of p -mTOR in between different 
grades of Oral Squamous Cell Carcinoma(OSCC). Increased intensity 
in the OSCC samples were observed when compared with normal 
mucosa. This value is also statistically significant (p=0.003). Also, 
when comparing the area of staining of p -mTOR in between different  
grades of OSCC statist ically significant difference (p =0.03) exists 
across these groups. Increased number of positive stained cells were 
observed in OSCC samples when compared to normal mucosa and the 
result  is stat istically significant (p=0.003).  
 
CONCLUSION: 
 We analysed the expression of p -mTOR as the first attempt in 
between different grades of OSCC and compared the expression with 
normal mucosa. Our present study reveals the significant expression of 
p-mTOR in Akt /mTOR/pS6 signaling pathway which act as a  
prognostic marker or target for molecular therapies. Further research 
with a larger number of sample size with clinicopathologic correlation 
and long term follow up will emphasize more towards the use of mTOR 
as a prognostic marker. It  will also be more interesting to correlate the 
presence and frequency of other molecular aberrations such as p-Akt  
and pS6 to trace out the role of entire Akt/mTOR/pS6 signali ng 
pathway in OSCC. It will also be useful for the development of new 
therapeutic strategies targeting on mTOR pathway.  
 
KEY WORDS: p-mTOR, Akt /mTOR/pS6 signaling pathway, Oral  
Squamous Cell Carcinoma, Immunohistochemistry.  
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INTRODUCTION 
 
 Squamous Cell Carcinoma is an epithelial  malignancy that exists 
in organs that are normally lined by squamous epithelium including 
skin, lips, mouth, esophagus, urinary tract, prostate, lungs, vagina and 
cervix
1
.
 
Oral Squamous Cell Carcinoma (OSCC) contributes to 95% of 
all forms of head and neck cancer and its incidence is increased by 
50% in the past decade
2
.
 
Dysregulation in the cell cycle and the 
proliferation of malignant cells leads to the loss of control mechanisms 
that ensure the normal function of tissues
3
.  Advances in diagnosis and 
therapeutic techniques for these lesions have extracted novel molecular 
targets, uncovered signal pathway dominance and advanced early 
cancer detection
4
.  
 
 In recent years, advances in molecular biology, r evealed several  
steps in carcinogenesis related to signaling pathways and enables us to 
look in to the molecular events and aberrations which leads to the 
cancer development and progression. Akt/ mTOR /pS6 signaling 
pathway has been recognised as one of the most commonly associated 
pathways in different types of human cancer,  including OSCC
5
.  
 
 The diagnosis of cancer relies on the analysis of tissue and 
cytology specimens which is obtained through various procedures. 
When a cell become cancerous, new antigens which are unfamiliar to 
the immune system appears on the cell surface. The immune system 
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recognises these new antigens called tumour antigens as foreign and 
may be able to contain or destroy the cancerous cells
6
.  
  
  Tumour marker is a molecule that indicates the likely presence 
of cancer or can also be defined as one which provides information 
about the likely future behaviour of an existing cancer (Eg –  abili ty to 
metastasize or to respond to therapy). Most of the existing tumour 
markers are chiefly useful in making a clinical decision after initial  
suspicion of cancer or its behaviour which has been already raised by 
more conventional means
6
.  
 
 mTOR (Mammalian Target of Rapamycin) is one of the major 
targets of activated Akt which in turn controls a n umber of downstream 
molecules, such as ribosomal protein pS6 that eventually regulates 
fundamental processes such as cell survival, proliferation, protein 
synthesis and angiogenesis
5
.  In response to various stimuli  such as 
nutrient, oxygen, insulin, growth  factors, adenosine triphosphate and 
tobacco metaboli tes mTOR is activated by Phosphorylation of Ser 2448 
via the Phosphatidylinositol 3 -kinase (PI3-K)/ Akt signaling pathway. 
This leads to subsequent activation of key modulators which are 
involved in protein synthesis
7
.
 
Dysregulations in upstream and 
downstream molecules of mTOR signaling takes place in 90 -100% of 
HNSCCs (Head and Neck Squamous Cell  Carcinomas) suggesting that  
markers and targets in the Akt/mTOR/pS6signaling pathway are 
especially of clinical significance
5
.
 
p-mTOR is an important 
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therapeutic target for Oral Squamous Cell  Carcinoma and an 
independent prognostic factor in the overall survival (OS) to assess 
high risk subgroups and as a guide to therapy
7
.
 
  
 The purpose of this study is to ana lyse the Immunohistochemical 
expression of phosphorylated form of mTOR in different grades of 
OSCC in comparison with normal mucosa, in order to assess the 
potential contribution of Akt/mTOR/pS6 signaling pathway aberrations 
in OSCC. 
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AIM AND OBJECTIVES 
 
AIM: 
            To analyse the Immunohistochemical expression of 
phosphorylated form of mTOR (p-mTOR) in different grades of OSCC 
in comparison with normal mucosa .  
 
OBJECTIVES: 
1.  To evaluate the immunohistochemical expression of p -mTOR in 
different grades of Oral  Squamous Cell Carcinoma  
2.  To compare the immunohistochemical expression of p -mTOR in 
different grades of Oral  Squamous Cell Carcinoma  
3.  To compare the immunohistochemical expression of p -mTOR in 
Oral Squamous Cell Carcinoma and normal  mucosa 
4.  To evaluate the area of staining of p -mTOR in different grades 
Oral Squamous Cell Carcinoma 
5.  To compare the area of staining of p -mTOR in different grades 
Oral Squamous Cell Carcinoma 
6.  To compare the area of staining of p -mTOR in Oral Squamous 
Cell Carcinoma and normal mucosa  
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REVIEW OF LITERATURE 
 
ORAL SQUAMOUS CELL CARCINOMA (OSCC)  
 Squamous Cell Carcinoma is one of the most common malignant 
tumours of oral cavity.  It constitutes about 90 -95% of all oral  
malignancies
8
.
 
 
ETIOLOGY:
 
 The etiology of OSCC is multifactorial inclusi ve of both 
intrinsic & extrinsic factors. It is predicted that more than a single 
factor is necessary to produce malignancy. The etiological factors 
include tobacco smoking, smokeless tobacco, betel quid (paan),  
alcohol, phenolic agents, radiation, iron de ficiency, vitamin A 
deficiency, syphilis, candidal infection, oncogenic viruses,  
immunosuppression, oncogenes and tumour suppressor gene s
2 , 9 ,1 0
. 
 
Tobacco: Tobacco consumption continues to remain as the most 
important risk factor as it  alone accounts for th e millions of cancer 
death annually. The most important carcinogens in tobacco smoke are 
the aromatic hydrocarbon benz-pyrene and the tobacco –  specific 
nitrosamines (TSNs) namely 4-(nitrosomethylamino)-1-(3-pyridyl)-1-
butanone (NNK) and N’ -nitrosonornicot ine (NNN). Certain other 
classes of enzymes that are involved in the activation or degradation of 
carcinogens and procarcinogens are termed as Xenobiotic Metabolising 
Enzymes (XME).  Hence, certain  XME genotype may increase 
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individual susceptibility to cancer through erogenous carcinogen 
metabolism which leads to increased carcinogen exposure
2
.  
 
Betel quid: Betel  quid (also referred to as pan or paan) contains betel  
leaf, areca nut, slaked lime and tobacco. Other ingredients are often 
added namely spices such as cardamom, cloves or aniseed to the quid 
in India. It is evident from the research studies that betel quid 
ingredients especially of tobacco and areca nut are having 
carcinogenic,  mutagenic and genotoxic potential
2
.
 
 
Alcohol: Consumption of alcohol has been shown to act synergist ically 
with tobacco and having increased risk of development of oral 
cancer.
2
Alcohol may also act as a solvent and increase the penetration 
of carcinogens in to target tissues
4
.  
 
Viruses: Human Papilloma Virus (HPV) positivity is higher in tumours 
of oral cavity (59%), pharynx (43%) and larynx (33%).HPV subtypes 
16 & 18 are more associated with malignant transformation
4 ,1 1
.
 
Epstein-Barr viruses and HPV are associated with carcinogenesis in 
oropharyngeal cancers & nasopharyngeal cancers respectively
1 2
.
 
 
Diet: Fruits and vegetables (high in vitamin A &C) are considered as 
protective in oral neoplasia, whereas meat and chilli  powder are 
thought to be risk factors
4 ,1 3
.  
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Family History of Head and Neck Squamous Cell Carcinoma (HNSCC): 
Family History of Head and Neck Squamous Cell Carcinoma is a risk 
factor. The ability to repair DNA which is damaged by tobacco 
carcinogens is defective in patients with family history of HNSCC
4
.  
 
Immune deficiency: A defective immune response, as seen in a Human 
Immunodeficiency Virus (HIV) infected individual, may predispose to 
cancer. OSCC of the lip is more common in transplant recipients 
receiving immunosuppressive therapy, but HIV infection does not 
predispose to intra-oral  squamous cell carcinoma
4
.  
 
Molecular changes in Oral cancer: Cancer occurs through multiple 
steps, each step is characterised by the sequential accumulation of 
additional genetic defects, followed by clonal expansion. The genetic 
alterations observed in head and neck cancer are sign ificantly due to 
oncogene activation and tumour suppressor gene inactivation which 
leads to de-regulation of cell proliferation and death
4
.  
 
Tumour Suppressor Genes(TSGs) and Growth Regulators: Growth 
regulators and TSGs act as transducers of negative grow th signals. 
Genetic alterations involving the tumour suppressor genes p16 & p53, 
are frequently noted in head and neck tumours. The gene can be 
inactivated by several mechanisms such as point mutations,  deletions 
and binding with cellular and viral protein s. p53 gene inactivation has 
been demonstrated in Squamous Cell Carcinoma
4
.  
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CLINICAL FEATURES: 
 OSCC may take several clinical forms. It may look like a 
leukoplakia, a verrucous leukoplakia, an erythroleukoplakia or an 
erythroplakia, any of which may devel op in to a necrotic ulcer with 
irregular, raised indurated borders or in to a broad based exophytic 
mass with a surface texture which may be verrucous, pebbled or 
relatively smooth. When traumatized, OSCC bleeds easily and most 
often becomes superficially secondarily infected. Large lesions may 
interfere with normal speech, mastication or swallowing
9
.
 
OSCC can be 
similar in most studies,  but  can  vary from country to country
1 4
.
 
 
 About two-thirds of OSCC are of substantial size and will have 
clinically detectable metastases to cervical lymph nodes at the time of 
diagnosis. The lymph nodes which are affected are firm and non -
tender to palpation &   fixed and matted lymph node has occurred if 
extracapsular spread invade in to the surrounding connective tissue . A 
high rate of local and regional recurrence, distant metastasis and 
mortality is  associated with high rate of local recurrence
9
.
 
 
HISTOPATHOLOGICAL FEATURES:  
  SCC arises from dysplastic surface epithelium 
histopathologically characterised by the presence  of invasive 
islands and cords of malignant squamous epithelial  cells  
  Irregular extension of lesional epithelium through the basement 
membrane and in to subepithelial connective tissue represents 
the invasion.  
Review of Literature 
 
9 
 
  Individual squamous cells & sheets or islands of cells are seen 
within the connective tissue without the presence of attachment 
to the surface epithelium.  
  The underlying adipose tissue, muscle or bone may be invaded 
by dysplastic epithelial cells .  
  Angiogenesis  is induced by lesional epithelium and 
desmoplastic changes occurs occasionally.  
  Lesional cells generally exhibits hyperchromatism & increased 
nuclear cytoplasmic ratio.  
  Cellular & nuclear pleomorphism  are seen at  varying degrees  
  Keratin pearls are evident & individual cell keratinisation  may 
also occur 
1 5
.  
  
GRADING: 
 Lesions are graded based on a 3 -point (Grades I to III) or a 4 -
point (Grades I to IV) scale.  The higher numerals denote the less 
differentiated tumours.  
  Well differentiated squamous cell  carcinoma :  A tumour 
which closely resembles it s parent tissue of origin,  grow at  a 
slower pace and metastasize later in its  course is called low 
grade, grade I or Well differentiated squamous cell carcinoma.  
  Poorly differentiated squamous cell carcinoma:  A tumour 
which shows much cellular & nuclear pl eomorphism, little or 
no keratin production & is difficult to identify its tissue of 
origin. It also metastasizes early in its  course and termed as 
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high grade, grade III or IV, Poorly differentiated or Anaplastic 
squamous cell carcinoma. 
  Moderately differentiated squamous cell carcinoma:  A 
tumour which shows the microscopic appearance in between 
these two extremes are considered as grade II or Moderately 
differentiated squamous cell carcinoma
1 5
.  
 
Grading of squamous cell  carcinoma –  Broder’s classification 
(1920): 
  Grade I: Well differentiated tumours - 75-100% of cells are 
differentiated  
  Grade II:  Moderately differentiated tumours - 50-75% of cells 
are differentiated  
  Grade III: Poorly differentiated tumours - 25-50% of cells are 
differentiated  
  Grade IV: Anaplastic tumours- 0-25% of cells are 
differentiated
1 6
.  
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mTOR (MAMMALIAN TARGET OF RAPAMYCIN)  
  
 The Mammalian Target of Rapamycin (mTOR)  is a serine - 
threonine protein kinase  and it is a main downstream target of the 
PI3/Akt  (Phopsphotidylinositol 3 kinase /protein kinase B) signaling 
pathway
1 7 ,1 8
.
 
It belongs to the PI3k related kinase family
7
.This 
pathway plays its  significant role in maintenance of overall cell  
survival, cell growth and cell proliferation
7
.  In addition, mTOR is also 
involved in protein and lipid synthesis, mitochondrial metabolis m, 
biogenesis and it negatively regulates autophagy
1 9
.
 
In response to  
various stimuli such as nutrient, oxygen, insulin, growth factors, 
adenosine triphosphate & tobacco metabolites, mTOR gets activated by 
phosphorylation of Ser 2448 (Serine) via the PI3/A kt signaling 
pathway. The activated (phosphorylated) mTOR is known as p-mTOR. 
Ultimately this leads to the subsequent activation of three key 
modulators in protein synthesis and they are
7
:   
 The eukaryotic translational factor,4E  
 The p70 ribosomal S6 kinase and  
 Elongation factor 2  
 
mTOR complexes:  
Two well defined multiprotein complexes have been identified and 
cloned: They are
2 0
:  
1.mTOR complex 1 (mTORC1)  
2.mTOR complex 2 (mTORC2)
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mTORC1: 
 mTORC1 comprises of mTOR,  GβL/LST8 and Regulatory 
Associated Protein of mTOR(RAPTOR). This complex promotes 
translation in response to different stimuli & maintains the t iming of 
cell growth
1 2
.
 
 
mTORC2: 
 mTORC2 comprises of mTOR,  GβL and Rapamycin Insensitive 
Component of mTOR (RICTOR). This complex stimulates cells t o 
increase in their size and mass
1 2
.
 
 
 Both of the mTOR complexes function significantly in 
cytoplasm. Higher eukaryotes (mammals, flies & worms) contain only 
one TOR gene
1 2
.
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RAPAMYCIN & RAPALOGS 
  
 Rapamycin is an antibiotic obtained from the bacterium 
Streptomyces hygroscopicus  which is found in soil of Easter island
2 1
.
 
Rapamycin was discoverd as a potent antifungal agent, but it  is also 
having the immunosuppressive effect . The immunosuppressant FK 506  
(Tacrolimus) and rapamycin are having similar chemical structures and 
both can binding to the same intracellular receptor,  FKBP12. 
Eventhough tacrolimus and rapamycin are binding to the same protein,  
they act by different mechanism of actions in cells. In addition to 
rapamycin, three rapamycin analogs (rapalogs) are identified now in 
humans. Rapalogs are having the same mechanism of action as 
rapamycin. Rapamycin has also been proposed to inhibit  mTOR by 
destabilising the mTOR –Raptor complex.  Inhibition of mTOR kinase 
activity is more effective for killing cancer cells which ex hibits 
increased mTOR signaling
2 2
.
 
 
mTOR KINASE INHIBITORS
 
 A small molecule which is formulated to compete with ATP in 
the catalytic site of mTOR inhibits all of the ki nase dependent 
functions of mTORC1& mTORC2. mTOR kinase inhibitors are 
formulated only to inhibit class I PI3 Kinases. So, the drugs which are 
inhibit ing both the PI3K/mTOR are having the therapeutic advantage
2 2
.
 
 
             
Inhibition of mTOR dependent signaling would reduce the cell  
growth & cell  proliferation. The drug named rapamycin (clinically 
 Review of Literature 
 
14 
 
known as sirolimus) specifically inhibits TOR, which results in 
reduced cell growth, cell cycle progression and reduce the rate of cell  
proliferation. Thus, rapamycin and its analogues (rapalogs) are 
currently being tested in clinical  trials to treat various carcinomas
2
.    
 
mTOR DEREGULATION IN ORAL SQUAMOUS CELL 
CARCINOMAS
 
 Overexpression of mTOR protein occurs as a result  of 
combination of upstream oncogene act ivation and downregulation of 
suppressor gene
1 4
.
 
PTEN (Phosphate and Tensin homolog detected on 
chromosome TEN) is a tumour suppressor gene. The major substrate 
for PTEN is PIP3 (Phosphotidylinositol 3,4,5 tri phosphate), a product 
of PI3/Akt signaling pathway. Therefore, the loss of PTEN function 
leads to increased levels of PI3 and hyperactivation of mTOR in oral 
squamous cell carcinomas.  The dysregulated mTOR expression was 
also reported on esophageal, salivary gland, hepatic, gastric, breast, 
bladder, bil iary tract  and lung cancers
7
.  
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                    PI3-Akt-mTOR SIGNALING PATHWAY 
 The PI3 pathway is the main signal transduction system which 
links the oncogenes and multiple receptor classes for many essential 
cellular functions. It is considered as the most commonly activated 
signaling pathway in human cancer. This pathway acts both as an 
opportunity and a challenge for cancer therapy. Receptor tyrosine 
kinases (RTKs),  G protein coupled receptors (GPCRs),  PI3Ks act  as  
major downstream effecto rs and transduce signals from different 
Growth factors and cytokines in to intracellular messages by generating 
phospholipids,  which in turn activates the serine/Threonine kinase A kt 
and other downstream effectors in the pathways. The tumour 
suppressor gene PTEN negatively regulates the PI3K pathway. Recent 
human cancer genomic studies have showed that many components of 
PI3K pathway are often  targeted by germline or somatic mutations in a 
broad spectrum of human cancers. Based on these findings and the fac t  
that PI3K and other kinases in the PI3K pathway are effectively suited 
for pharmacologic intervention, this pathway is considered as one of 
the most attractive targets for therapeutic intervention in cancer
2 4
.
 
PI3Ks have been divided into three classes  based on their structural  
characteristics and substrate specificity.  Of these, the most commonly 
studied are class I enzymes which are activated directly by cell surface 
receptors. Class I PI3Ks are further  subdivided into class IA enzymes ,  
activated by RTKs, GPCRs and certain oncogenes like small G protein 
Ras and class IB enzymes,  which is regulated specifically by GPCRs
2 4
.  
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The PI3K-Akt - mTOR signaling in cancer cell  growth and survival  
 The family of lipid kinases termed PI3K are considered  as key 
regulators in various essential cellular processes such as cell survival,  
growth and differentiation. The  PI3K pathway has various important 
nodes that play a  significant role in this pathway which results in a 
diversity of functional outcomes. The Akt -mediated activation 
of downstream targets, including mammalian target of  rapamycin 
(mTOR) increases cell proliferation and the  regulation of translation in 
response to growth factors by the phosphorylation of the protein 
synthesis machinery. This translational p romotion by mTOR includes 
the phosphorylation of ribosomal protein S6  kinases (s6K) and 
4E-binding protein 1 (4E-BP1)  the latter of which ultimately results 
in release of eukaryotic  translation initiation factor 4E (eIF4E), which 
has known anti-apoptotic activities. These effects are  counteracted by 
tuberous sclerosis complex-1  (TSC1) -TSC2 complex, which has 
inhibitory effects on 4E-BP1 and eIF4E. Akt also phosphorylates 
and inhibits TSC2, which depicts the complexity of this  pathway.  
Rapamycin and its analogues are capable of inhibiting mTOR, but this 
can result in activation of upstream  proteins such as Akt, due to the 
loss of a feedback loop mechanism. In addition, the PI3K-Akt pathway 
also interacts with  complex molecular mechanism which controls 
cellular energy control and glucose metabolism.  The PI3K signaling 
also controls growth,  proliferation, senescence and angiogenesis.  
These processes are mediated by vascular endothelial growth  factor 
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(VEGF) transcriptional activation and hypoxia-  inducible factor-1alpha 
(HIF-1α) expression2 5 .  
 
The PI3-KINASE /AKT signaling pathway delivers an anti -
apoptotic signal:  
 Inhibition of PI 3-kinase accelerates apoptosis  and an activated 
form of the serine/threonine kinase Akt, a downstream effector of PI3 -
kinase blocks apoptosis
2 6
.
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Figure 1.  mTOR pathway 
Figure depicts that the Growth factors & their receptors send signals to 
PI3K (Phosphotidylinositol 3-kinase) which send downstream signals 
to Akt (Protein kinase B) which send transmit signals to mTOR  
(Mammalian Target of Rapamycin). mTOR phosphorylates & activates  
p70S6K (ribosomal kinase) and inhibits  4 EBP1 (translational factor  
binding protein). The overall pathway plays important role in 
maintaining protein synthesis, cell growth and cell survival
2 7 , 2 8 ,2 9
.
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EXPRESSION OF p-mTOR IN HNSCCs & IN ORAL LESIONS 
 
Panomwat Amornphimoltham et al  in 2004 evaluated the status of 
activation of Akt in various stages of Squamous Cell C arcinoma 
development in mice and in clinical samples from HNSCC patients. By 
immunohistochemical analysis, using a recently developed 
phosphorylation state-specific antibody, they depicted that Akt 
activation correlates closely with the progression of mouse skin 
squamous cell carcinoma. They also observed that activation of Akt is 
a frequent event in human HNSCC because active Akt can be detected 
in these tumors with a pattern of expression and localization which 
correlates with the progression of the lesions.  Based on these 
observations, Akt was constitutively activated in a large fraction of 
HNSCC-derived cell  lines. They also provide evidence that the Akt  
signaling pathway may represent a biologically relevant target for a 
novel antineoplastic agent, UCN-01 (7-hydroxystaurosporine) , which 
recently is  shown to be active in cellular and xenogra ft models
3 0
.  
 
H. A. R. Pontes et al  in 2009  did a study to evaluate the 
immunoexpression of p -Akt and Metallothionein (MT) proteins in 
dysplasic and neoplasic oral lesions.  Immunohistochemical studies 
were carried out on 10 normal epithelium, 30 OL and 15 OSCC 
parafﬁn-embedded samples. Immunoperoxidase reactions for p -Akt and 
MT proteins were applied on the specimens and the positivity of the 
reactions were calculated for 1000 epithelial cells . A signiﬁcant 
difference was observed in the immunoexpression for  p-Akt and MT 
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when the OSCC samples were compared with normal and dysplastic 
epithelial groups. Based on the data obtained, p -Akt and MT activation 
may play an important role in the conversion of a potentially malignant 
oral lesion to a malignant lesion
3 1
.
 
 
Ho-Tai Wu et al  in 2009  evaluated the role of phosphorylated Akt (p -
Akt) in oral carcinogenesis induced by nicotine and alkaline 
environments.  By using Immunohistochemistry, (IHC) p -Akt 
expression in cancerous (n = 30) precancerous (n = 30), and normal 
mucosa tissues (n = 10) were studied.  Higher p -Akt expression was 
noted in cancerous group than in normal mucosa (P = 0.0002) and 
precancerous (P = 0.0049) groups.  The dose-dependent increase in p -
Akt by nicotine treatment was specifically observed. Higher  p-Akt 
expression was also expressed in more alkaline environment
3 2
.
 
 
Cheryl Clark et al  in 2010  evaluated the biomarkers mTOR, Akt, 
4EBP1, and S6 kinase, signaling components in HNSCC patients and 
compared i t with normal mucosa. Expression of phosphorylat ed Akt 
and phosphorylated mTOR were significantly  increased in tumors 
compared to non-cancer oral mucosa samples (p=0.004 and p=0.026 
respectively).  p-mTOR and p4EBP1 expression were higher in patient 
junctional zones (p=0.017 and p=0.022 respectively) and  no difference 
in p-AKT or p-S6 expression in HNSCC patients junctional zone 
compared to tumors. IHC revealed p -mTOR expression was 81.9% 
sensitive and 100% specific in differentiating cancer from non -cancer 
mucosa, while p-4EBP1 expression by IHC was only 50.0% sensitive 
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and 95.5% specific for differentiating normal mucosa from HNSCC 
(p<0.01)
3 3
.  
 
Georgios Prodromidis  et al  in 2013 evaluated the activation status of 
Akt,  mTOR, and pS6 in oral lichen planus (OLP) and compared i t with 
oral premalignant and malignant lesions and normal oral mucosa (NM). 
Immunohistochemistry for p-Akt, p-mTOR, and phospho-pS6 was 
performed in 40 OLP, 20 Oral Leukoplakias (OL), 10 OSCC and 10 
control samples of normal mucosa.  Nuclear p-Akt expression was 
observed in majority of cases in all categories, being predominantly 
higher in OL. Cytoplasmic p-Akt and p-mTOR staining was observed 
only in few OLP cases,  being significantly lower compared to OL and 
OSCC. Phospho-pS6 showed cytoplasmic positivity in majority of OLP 
cases, which however was significantly lower compared to OL and 
OSCC. They concluded that cytoplasmic p -Akt,  p-mTOR and phospho-
pS6 levels were lower in OLP when compared to OL and OSCC
5
.  
 
Luis Silva Monteiro et al  in 2013  studied the expression of 
phosphorylated mammalian target of rapamycin (p -mTOR) and 
phosphatase and tensin homolog deleted on chromosome TEN (PTEN) 
in oral squamous cell carcinomas (OSCCs) and correlated them with 
clinicopathologic characteristics and prognosis. They studied p -mTOR 
and PTEN protein expression by immunohistochemistry in 72 cases of 
OSCCs. p-mTOR expression was noted in 46 (63.9%) cancers and 
PTEN expression was absent in 22 (30.6%). The p -mTOR was 
suggested as a reliable biological marker to  identify high-risk 
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subgroups and they act  as a guide to therapy. In addition, the higher 
expression levels of p-mTOR suggests that this protein may act as a 
promising therapeutic target for OSCC
7
.
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p-mTOR IN OTHER LESIONS 
            J Boone et al  in 2008 investigated the expression of p -mTOR 
(Ser2448) immunohistochemically in formalin -fixed, paraffin-
embedded Oesophageal SCCs (OSCCs). Normal oesophageal epithelium 
shows negativity for p-mTOR. Activated mTOR expression was located 
in the cytoplasm of  oesophageal tumour cells. 26 (25%) of 105 
assessable OSCCs expressed tumour cells with positive staining for 
activated mTOR. Activated mTOR expression was associated with a 
lesser degree of differentiation only (p = 0.024). No correlation was 
observed between p-mTOR and the proliferation marker Ki -67. He 
concluded that activated mTOR can be detected  in one-quarter of 
OSCCs
3 4
.
 
 
Alberto M Martelli  et al  in 2009 explained in his  review about how 
PI3K/Akt/mTOR signaling network is  constitutively active in acute 
myelogenous leukemia (AML). He concluded that the limit of 
acceptable toxicity for standard chemotherapy has been reached in  
AML and new  therapeutic  strategies  are  needed.  Targeting the 
PI3K/Akt/mTOR signaling network with small molecule inhibitors , 
alone or in combinations with other drugs, may provide less toxic and 
more efficacious treatment of AML patients
3 5
.
 
 
Sunil Badve et al  in 2010  analysed the nuclear and cytoplasmic 
phospho-Akt (p-Akt) expression by immunohistochemistry in a breast  
cancer tissue microarray (n = 377) and corelated these data with the 
expression of estrogen receptor (ER)  progesterone receptor (PR) and 
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FOXA1. Nuclear localization of p  Akt (nuclear-p AKT) was associated 
with long-term survival (P 0.004). Within the ER,  PR subgroup, 
patients with nuclear -p Akt positivity had better survival when 
compared to nuclear-p Akt–negative patients (P < 0.05).  TCL1 B  
(T Cell Leukemia/ Lymphoma 1 B)  family proteins play significant role 
in regulating nuclear transport  and/or activation of A kt. TCL1B  is 
overexpressed in ER - positive compared with ER-negative breast  
cancers and in lung metastasis–free breast cancers 3 6 .  
 
Di Wang et al  in 2011  analysed the significance of mammalian target 
of rapamycin (mTOR) and its active form, p -mTOR in colorectal 
carcinomas. Immunohistochemistry was used to find the expression of 
mTOR and p-mTOR proteins in 108, 40 and 40 tissue samples from 
colorectal carcinoma, normal colonic mucosa and adenomatous polyps 
samples, respectively.  The correlation of mTOR and p-mTOR 
expression with clinicopathological characteristics of colorectal 
carcinoma was observed.  The positive rates of mTOR and p -mTOR 
were significantly increased in colorectal carcinoma (61.1% and 
61.1%, respectively,  p<0.05) than in normal colonic muco sa (7.5% and 
2.5%) and in adenomatous polyps (27.5% and 20%).  Overexpression of 
total  mTOR protein was associated with T1/T2 stage tumors, lymph 
node metastasis, distant metastasis) and degree of differentiation. In 
addition, p-mTOR overexpression was linked with degree of 
differentiation and TNM stage.  The overexpression of mTOR and p -
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mTOR may play important roles in colorectal carcinogenesis in relation 
to the degree of differentiation, invasiveness and metastasis
3 7
.  
 
Anna Tamburrino et al  in 2012 analysed the phosphorylation status of 
proteins of the RAS/MEK/ERK and PI3K/A kt/mTOR pathways in 53 
Medullary thyroid carcinoma (MTC) tissues (18 hereditary, 35 
sporadic), including 51 primary MTCs and 2 cases with only lymph 
node metastases (LNM).  In addition, they also analysed the functional 
relevance of the mTOR pathway by measuring cell viability,  motility 
and tumorigenicity upon mTOR chemical blockade.  Phosphorylation of 
ribosomal protein S6 (pS6), a downstream target of mTOR, was 
observed in 49 (96%) of 51 primary MTC samples. This was a ssociated 
with activation of Akt  (phospho-Ser473, S > 1) in 79% of cases 
studied. The Akt  /mTOR pathway is activated  in MTC, particularly,  in 
LNMs
3 8
.
 
 
Zhi-Jun Sun et al  in 2012  evaluated the efﬁcacy of rapamycin 
treatment in chemoprevention and chemotherapy of tumorigenesis in a 
genetically deﬁned mouse model of head and neck squamous cell 
carcinoma (HNSCC).  Knockdown of Tgfbr1  (Transforming Growth 
factor binding receptor 1)  and /or PTEN in human HNSCC cell lines 
leads to activation of mTOR activity complex 1 and increased levels of 
survivin. Chemopreventive  rapamycin treatment delayed the onset of 
the HNSCC tumors and prolonged survival in 2cKO mice significantly.  
These ﬁndings represent that , tumorigenesis in 2cKO HNSCC is 
associated with activation of the Akt/mTOR/survivin pathway and 
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inhibit ion of this pathway can be achieved by rapamycin treatment 
successfully
3 9
.  
 
Tjinta Brinkhuizen et al  in 2014  did immunohistochemical stain ing of 
formalin-fixed, paraffin-embedded Basal cell carcinoma (BCC) (n = 
45) and Trichoepithelioma (TE) (n = 35) samples to assess activity of 
HIF1 (Hypoxia inducible factor -1 alpha), mTORC1 and their most 
important target genes. They concluded that HIF an d mTORC1 
signalling seems to be active in both BCC and TE & there are no 
appreciable differences between the two with respect to pathway 
activity.  HIF, mTORC1 and their target genes are not a reliable 
diagnostic tool for the discrimination of BCC and TE
4 0
.
 
 
Shu-Ting Pan
,  
et al  in 2015 investigated the effects of plumbagin 
(PLB) on cell cycle distribution, apoptosis, and autophagy, and the 
underlying mechanisms in the human TSCC cell  line SCC25. The 
results of their study revealed that PLB exerted potent ind ucing effects 
on cell cycle arrest,  apoptosis, and autophagy in SCC25 cells.  PLB 
inhibited phosphatidylinositol 3 kinase (PI3K)/protein kinase B 
(Akt)/mammalian target of rapamycin (mTOR), glycogen synthase 
kinase 3β (GSK3β),  and p38 mitogen -activated protein kinase (p38 
MAPK) pathways as represented by the alteration in the ratio of 
phosphorylation level over total  protein expression level,  which 
contributes to the inducing effect of autophagy. These results predict 
that PLB promotes cellular apoptosis and  autophagy in TSCC cells 
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involving p38 MAPK and PI3K/Akt/mTOR -mediated pathways with 
contribution from the GSK3β and ROS -mediated pathways4 1 .  
 
V Vasko et al  in 2017  analysed 46 thyroid cancer, 20 thyroid follicular 
adenoma and adjacent normal tissue  samples by immunohistochemistry 
for activated Akt (pAkt), Akt 1, 2 and 3 and p27 expression. Akt 
activation was noted in 10/10 follicular cancers, 26/26 papillary 
cancers and 2/10 follicular variant of papillary cancers, but in only 
4/66 normal t issue samples and 2/10 typical benign follicular 
adenomas. Immunoactive pAkt was highest in regions of capsular 
invasion and was localised to the nucleus in follicular cancers and the 
cytoplasm in papillary cancers, except for invasive regions of papillary 
cancers where i t was localised to both regions. Immunoactive  Akt 1,  
but not Akt 2 or Akt 3,  correlated with pAkt localisation and nuclear 
pAkt, was associated with cytoplasmic expression of p27. In vitro 
studies using human thyroid cancer cells explained that  nuclear 
translocation of Akt 1 and pAkt  were associated with cytoplasmic p27 
and cell invasion and migration. Cell migration and the localisation of 
Akt 1, pAkt and p27 were inhibited by PI3 kinase, but not by MEK  
(MAPK/ERK kinase) inhibition. They concluded that nuc lear activation 
of Akt 1 plays significant role in thyroid cancer progression
4 2
.
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MATERIALS AND METHODS 
 
STUDY DESIGN AND PATIENT SELECTION:  
  This study was conducted on the archival retrieved 
formalin fixed, paraffin embedded tissues obtained from the 
Department of Oral  Pathology, Adhiparasakthi Dental College and 
Hospital, Melmaruvathur and from private hospitals. The study group 
included 21 cases of histologically diagnosed Oral Squamous Cell 
Carcinoma (7 cases of well differentiated squamous cell carcinoma, 7 
cases of Moderately differentiated Squamous Cell Carcinoma and 7 
cases of Poorly differentiated Squamous Cell Carcinoma). Control 
group includes biopsies from the normal buccal mucosa adjacent to the 
site of surgery during the surgical removal of third molar in 10 
patients.  
 
 Two subsequent sections, each 3µ thickness were cut f or each 
sample, from formalin fixed, paraffin embedded tissues of 
histologically diagnosed Oral Squamous Cell Carcinoma and normal 
buccal mucosa.  
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MATERIALS  
PARAFFIN BLOCKS: 
 Paraffin embedded t issues of histologically confirmed cases of 
Oral Squamous Cell Carcinoma were used in the study.  
 
EQUIPMENTS:  
  Microtome (Thermo scientific,  MICROM HM340E)  
  Paint brush 
  Disposable microtome blades  
   Hot plate  
   Hot water bath  
  Pathn Situ positively charged slides  
   Pressure cooker (5 Liters)  
   Measuring Jars  
   Coplin Jars  
   Electronic Timer  
   Absorbent wipes  
   Coverslip for slides  
  Binocular Light Microscope (Olympus CX21i)  
  Micropipette  
  Micropipette tips  
  Rectangular steel trough  
  Tweezer 
  Induction stove 
  Incubator (Hitech Equipments)  
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  Liquid repellent slide marking pen  
  Deparaffinization stainless steel staining trough and rack  
  pH meter (E1 digital  pH meter)  
  A DELTA PLAN2 AP40 Trinocular Light Microscope with 
camera Head  
 
ANTIBODIES: 
1. Primary antibody   
(a) Anti p-mTOR (Ser 2448) Rabbit polyclonal Antibody –  Bioss 
Antibodies U.S.A 
2. Secondary kit (PolyExcel HRP/DAB Detection System) –  Pathn Situ  
Biotechnologies Private Limited  
(a) PolyExcel H2O2  
(b) PolyExcel Target Binder  
(c) PolyExcel Poly HRP 
(d) PolyExcel stun DAB –  Chromogen  
(e) PolyExcel stun DAB –  Buffer  
 
REAGENTS USED:  
  Tris Buffer –  50X concentration (Pathn Situ Biotechnologies 
Private Limited)  
  Immuno wash Buffer –  25X concentration (Pathn Situ 
Biotechnologies Private Limited)  
   Distilled water  
   Xylene 
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  100 % Ethanol  
  95 % Ethanol  
  70 % Ethanol  
  50 % Ethanol  
  Harris Hematoxylin  
  DPX Mountant  
IMMUNOHISTOCHEMISTRY PROCEDURE:  
 Formalin fixed paraffin embedded tissues were sectioned at  3µm 
and mounted on charged slides and incubated for 45 minutes at 
60C 
 For Deparaffinization & Rehydration:  
1.Slides were washed two times in xylene for 3 minutes each time at 
room temperature(RT).  
2. Slides were washed in xylene 1:1 with 100% ethanol for 3 minutes at 
RT. 
3.Slides were washed two times in 100% ethanol for 3 minutes at  RT.  
4.Slides were washed two times in 95% ethanol for 3 minutes at RT.  
5.Slides were washed in 70% ethanol for 3 minutes at RT.  
6.Slides were washed in 50% ethanol for 3 minutes at RT.  
7.Slides were rinsed gently with running distilled water for 5 minutes 
at RT. 
 Antigen retrieval done for 15 - 20 minutes (up to 3 whistles in 
pressure cooker)  
 Cooled for minimum of 30 minutes  
 Washed in distilled water, 2 changes, 2 minutes each  
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 Washed in PBS / TBS for 2 minutes  
 Circles were marked enclosing the section using liquid repellent 
pen  
 Endogenous peroxidase blocking was done by adding PolyExcel 
H2O2  on the section, keep for 30 minutes  
  Washed in wash buffer for 5 minutes,  3 changes  
 Primary antibody was added and kept for overnight incubation in 
a moist chamber  
 Washed in wash buffer for 5 minutes, 3 changes  
  Poly Excel Target Binder reagent was added and incubated for 
30 minutes  
 Washed in wash buffer for 5 minutes, 3 changes  
 Poly excel HRP was added and incubated for 45 minutes  
  DAB solution was prepared (1 ml of DAB buffer + 1 drop DAB 
chromogen, mix well)  
 Washed in wash buffer for 5 minutes, 3 changes  
 Working DAB chromogen was added and kept for 10 minutes, 
then washed in distil led water.  
 Counterstained with hematoxylin for 30 seconds  
 Washed in running tap water for 5 minutes  
 Dehydrated through successive changes of alcohol and clear with 
xylene 
 Dried and mounted with DPX 
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POSITIVE CONTROL 
 Positive control section includes human testis for p -mTOR and 
was treated in the same manner as the test groups.  
 
NEGATIVE CONTROL 
 One section of test sample was selected and treate d in the same 
manner as the test  groups except that, the primary antibody was 
omitted.  
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Figure 2: Primary and Secondary Antibody kit  
 
 
Primary antibody p-mTOR (Rabbit polyclonal Antibody)  & 
Antibody diluent  
    
  Secondary kit                        DAB Chromogen  
    [H2O2, Target Binder, Poly HRP]        and DAB buffer 
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Figure 3: Reagents used 
 
Tris –  EDTA 
 
Hematoxylin  
 
Wash Buffer 
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Figure 4:  Equipments used  
 
Deparaffinization stainless steel staining trough and rack  
 
   
     Micropipette                             Incubator 
 
 
Reagent blocker 
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Electronic Timer 
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RESULTS 
 
 The study group included formalin fixed paraffin embedded 
tissue blocks of normal buccal mucosa and Oral Squamous Cell 
Carcinoma (OSCC). It was divided in to 10 cases of normal buccal 
mucosa,21 cases of Oral Squamous  Cell Carcinoma of which 7 cases of 
Well differentiated Squamous Cell Carcinoma,7 cases of Moderately 
differentiated Squamous Cell Carcinoma and 7 cases of Poorly 
differentiated Squamous Cell  Carcinoma.  
 
 A total of 31 cases (n=31) were examined for the 
Immunohistochemical expression of p -mTOR which includes normal 
buccal mucosa (n=10) and OSCC (n=21).  
 
 Kruskall Wallis test was done for analysing the 
immunohistochemical expression and area of staining for p -mTOR.  
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Evaluation & Comparison of Immunohistochemical expression of p -
mTOR in different grades of Oral Squamous Cell Carcinoma  
 Out of 7 Cases of well differentiated squamous Cell Carcinoma, 
the immunoreactivity for intensity of staining p -mTOR showed positive 
expression in 5 cases (71%) and 2 cases (28%) did not show any 
expression. Among the positive 5 cases (71%), 4 cases (57%) showed 
mild staining,1 case (14%) showed moderate intensity of staining and 
none of the case (0%) showed intense staining. Out of 7 Cases of 
Moderately differentiated squamous Cell  Carcinoma, the 
immunoreactivity for intensity of staining p -mTOR showed positive 
expression in 3 cases (42%) and 4 cases (57%) did not show any 
expression. Among the positive 3 cases (42%), 2 cases (28%) showed 
mild staining,1 case (14%) showed moderate intensity of staining and 
none of the case (0%) showed intense staining. Out of 7 Cases of 
Poorly differentiated Squamous Cell Carcinoma none of the cases (0%) 
showed positivity (Table 1& Graph 1).  
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Table 1 :  Evaluation & Comparison of immunohistochemical 
expression of p-mTOR in different grades of Oral Squamous Cell 
Carcinoma  
GROUPS 
NO OF 
CASES 
SCORES 
MEDIAN 
STAINING 
INTENSITY 
IQR 
VALUE 
p-
VALUE 
No 
stain 
(0) 
Mild 
staining 
(1) 
Moderate 
staining 
(2) 
Intense 
staining 
(3) 
Well 
differentiated 
7 2 (28%) 4 (57%) 1(14%) 0 (0%) 1 1 
 
0.03 
Moderately 
differentiated 
7 4 (57%) 2 (28%) 1 (14%) 0 (0%) 0 1 
Poorly 
differentiated 
7 
7 
(100%) 
0 (0%) 0 (0%) 0 (0%) 0 0 
 
Comparison of intensity of staining is statistically significant  across 
these groups as p-value is 0.03  (with p-value <0.05)  
Graph 1 :  Evaluation & Comparison of immunohistochemical 
expression of p-mTOR in different grades of Oral Squamous Cell 
Carcinoma  
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Evaluation & Comparison of immunohistochemical expression of p -
mTOR in Oral Squamous Cell Carcinoma and normal mucosa  
 Out of 21 Cases of Oral Squamous Cell Carcinoma, the 
immunoreactivity for intensity of staining p -mTOR showed positive 
expression in 8 cases (38%) and 13 cases (61%) did not show any 
expression. Among the positive 8 cases (38%), 6 cases (28%) showed 
mild staining,2 cases (9%) showed moderate intensity of staining and 
none of the case (0%) showed intense st aining. Out of 10 Cases of 
normal mucosa, none of the cases (0%) showed positivity (Table 2 & 
Graph 2).  
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Table 2 :  Evaluation & Comparison of Immunohistochemical 
expression of p-mTOR in Oral Squamous Cell Carcinoma and 
normal mucosa 
GROUPS 
NO OF 
CASES 
SCORES 
MEDIAN 
STAINING 
INTENSITY 
IQR 
VALUE 
p-
VALUE 
No 
stain 
(0) 
Mild 
staining 
(1) 
Moderate 
staining 
(2) 
Intense 
staining 
(3) 
Oral 
Squamous 
Cell 
Carcinoma 
21 
13 
(61%) 
6(28%) 2 (9%) 0(0%) 4 2 
 
0.003 
Normal 
mucosa 
10 
10 
(100%) 
0(0%) 0(0%) 0((0%) 0 0 
 
Comparison of intensity of staining is statistically significant  across 
these groups as p-value is 0.003  (with p-value <0.05)  
 
Graph 2 :  Evaluation & Comparison of Immunohistochemical 
expression of p-mTOR in Oral Squamous Cell Carcinoma and 
normal mucosa 
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Evaluation & Comparison of area of staining of p -mTOR in 
different grades of Oral Squamous Cell  Carcinoma:  
 Out of 7 Cases of Well differentiated Squamous Cell Carcinoma, 
the immunoreactivity for area of staining of p -mTOR showed posit ive 
expression in 5 cases (71%) & 2 cases (28%) did not show any 
expression. Among the positive 5 cases (71%), 3 cases (42%) showed 
<20% of posit ive cells,1 case (14%) showed 20 -50% of positive cells 
and 1 case (14%) showed >50% of positive cells. Out of 7 Cases of 
Moderately differentiated squamous Cell  Carcinoma, the 
immunoreactivity for area of staining of p -mTOR showed positive 
expression in 3 cases (42%) and 4 cases (57%) did not show any 
expression. Among the positive 3 cases (42%), 2  cases (28%) showed 
<20% of posit ive cells and 1 case (14%) showed > 50% of positive 
cells.  Out of 7 Cases of Poorly differentiated Squamous Cell 
Carcinoma none of the cases (0%) showed positivity.  
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Table 3 :  Evaluation & Comparison of area of staining of p-mTOR 
in different grades of Oral Squamous Cell Carcinoma:  
GROUPS 
NO OF 
CASES 
SCORES  
MEDIAN 
AREA OF 
STAINING 
 
IQR 
VALUE 
p- 
VALUE 
No 
positive 
cells (0) 
<20% 
of 
positive 
cells (1) 
20-50% 
of 
positive 
cells (2) 
>50% 
of 
positive 
cells (3) 
Well 
differentiated 
7 2(28%) 3(42%) 1(14%) 1(14%) 1 2 
 
0.03 
Moderately 
differentiated 
7 4(57%) 2(28%) 0(0%) 1(14%) 0 1 
Poorly 
differentiated 
7 7(100%) 0(%) 0(0%) 0(0%) 0 0 
 
Comparison of area of staining is statistically significant  across these 
groups as p-value is 0.03  (with p-value <0.05)  
 
Graph 3 :  Evaluation & Comparison of area of staining of  p -mTOR 
in different grades of Oral Squamous Cell Carcinoma  
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Comparison of area of staining of p -mTOR in  Oral Squamous  Cell  
Carcinoma and normal mucosa:  
 Out of 21 Cases of Oral Squamous Cell Carcinoma, the 
immunoreactivity for area of staining of p -mTOR showed positive 
expression in 8 cases (38%) & 13 cases (61%) did not show any 
expression. Among the positive 8 cases (38%), 5 cases (23 %) showed 
<20% of posit ive cells,1 case (14%) showed 20 -50% of positive cells 
and 2 cases (9%) showed >50% of positive cells. Out of 10 normal  
mucosa none of the cases (0%) showed positivity.  
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Table 4 :  Comparison of area of staining of p-mTOR in  Oral 
Squamous Cell  Carcinoma and normal mucosa:  
 
 
GROUPS 
 
NO OF 
CASES 
SCORES  
MEDIAN 
AREA OF 
STAINING 
 
IQR 
VALUE 
p-
VALUE 
No 
positive 
cells (0) 
<20% of 
positive 
cells (1) 
 
20-50% of 
positive 
cells 
(2) 
>50% of 
positive 
cells (3) 
Oral 
Squamous 
Cell 
Carcinoma 
21 13(61%) 5(23%) 1(14%) 2(28%) 3 3 
 
0.003 
Normal 
mucosa 
10 10(100%) 0(0%) 0(0%) 0(0(%) 0 0 
 
Comparison of area of staining is statistically significant  across these 
groups as p-value is 0.003  (with p-value <0.05)  
 
Graph 4 :  Comparison of area of staining of p -mTOR in Oral 
Squamous Cell  Carcinoma and normal mucosa:  
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Figure 5: Low power view (10x) showing showing expression of  
p-mTOR in positive control (Testis)  
 
 
Figure 6: High power view (40x) showing expression of p -mTOR in 
positive control (Testis)  
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Figure 7: Low power view (10x) showing moderate expression of  
p-mTOR in Well differentiated Squamous Cell Carcinoma.  
 
 
Figure 8: High power view (40x) showing moderate expression of  
p-mTOR in Well differentiated Squamo us Cell Carcinoma.  
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Figure 9: Low power view (10x) showing moderate staining in 
Moderately differentiated Squamous Cell Carcinoma  
 
 
Figure 10: High power view (40x) showing moderate staining in 
Moderately differentiated Squamous Cell Carcinoma  
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Figure 11: Low power view (10x) showing negative staining in 
Poorly differentiated Squamous Cell Carcinoma  
 
 
Figure12: High power view (40x) showing negative staining in 
Poorly differentiated Squamous Cell Carcinoma  
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DISCUSSION 
 
   Oral Squamous Cell Carcinoma consti tutes about 95% of all  
forms of head & neck cancer
3
.
 
Its incidence is high in many countries 
8 
and its incidence is increased by 50% for the last decade
3
.
 
The highest  
incidence and prevalence of OSCC is est ablished in the Indian 
subcontinent where the risk of OSCC occurrence is increased by the 
prevalent habits  of chewing tobacco, betel quid ,  areca nut and the 
regular drinking of alcoholic beverages
1 8
.Oral tumorigenesis is a 
multistep process in which cells accumulate disparate complement 
mutations which allows them to escape from normal cellular and 
environmental constraints on proliferation
3
. It  is caused due to 
sequential accumulation of multiple gene alterations. The aberrations 
may occur in a number of ce llular signaling pathways. One such key 
pathway is PI3/Akt/mTOR pathway. Molecular aberrations in this 
pathway may act as prognostic markers or targets for molecular 
therapies
7
.  
 
 m-TOR is a serine threonine kinase and it is a member of PI -3 
kinase family
1 4 ,4 3
.
 
It  plays an important role in maintaining the cell  
growth, cellular nutrient and energy status
4 4
.
 
The significance of 
phosphorylated mTOR remains unceratin
7
.
 
So, in the current study, 
Immunohistochemical expression of p-mTOR in different grades of 
OSCC was evaluated in order to assess the potential contribution of 
Akt /mTOR/ pS6 signaling pathway aberrations in OSCC.  
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 In the present study, a total of 31 samples, out of which 21 cases 
of Oral Squamous Cell Carcinoma and 10 cases of normal buccal 
mucosa were evaluated for the expression of p -mTOR using standard 
IHC procedure with anti p -mTOR antibody (rabbit polyclonal antibody-
Bioss USA). In this study, OSCC was graded according to Broder’s 
classification (1920) as Grade I –  Well differentiated (75 to 100% of 
cells are differentiated), Grade II –  Moderately differentiated (50 to 75 
% of cells are differentiated) and Grade III –  Poorly differentiated (25 
to 50% are differentiated)
1 6
.
 
 
 In our study, on evaluating and comparing the p -mTOR 
expression in different grades of OSCC, the staining intensity was 
found to be statistically significant between the different grades of 
OSCC (p value = 0.03).  This is  in accordance with the study conducted 
by Geogios Prodromidis et al . ,  Hyun Lee et al. ,  Noske Aurelia et al . ,  
and Boone et al .  
 
 Out of 7 cases of Well differentiated OSCC, 5 cases (71%) 
showed positive staining, out of 7 cases of Moderately differentiated 
OSCC, 3cases (42%) showed positive staining. All 7 cases of Poorly 
differentiated OSCC showed negative ex pression (Table 1& Graph 1).  
 
 These results were similar to the study conducted by Hyun Lee 
et al . ,  (p=0.008) who assessed the expression of p -mTOR in Small Cell  
Lung Cancer
4 5
.
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 Noske Aurelia et al.,  (2008)  investigated the activation of 
mTOR in a subgroup of ovarian Carcinomas and corelate d it with 
prognosis. They concluded that for the first -time that higher p-mTOR 
expression was associated with primary Ovarian Carcinoma and was 
significantly associated with better overall survival (p=0.003). Even in 
our present study higher p-mTOR expression is associated with low 
grade tumours. The results of our study matched with this study
4 6
.
 
 
 In the present study, out of 7 cases of Poorly differentiated 
OSCCs, none of the case showed the expression for p -mTOR. These 
results were inconsistent with the study conducted by Boone et al . ,  
who assessed the expression of p -mTOR in squamous cell carcinoma of 
Oesophagus. They concluded that activated mTOR expression is 
associated with lower degree of differentiation (p=0.024)
3 4
.
 
 
 mTOR is one of the major targets of activated Akt, which in turn 
regulates a number of downstream molecules such as ribosomal protein 
pS6, which controls the fundamental  cell processes such as cell 
survival, proliferation, protein synthesis and angio genesis
5 ,4 7
.  
Dysregulations in upstream and downstream molecules of mTOR 
signals may contribute to aberrations in Akt /mTOR /pS6 signaling 
pathway, which is highly conserved and controlled by multistep 
process
4 8 ,4 9 ,5 0
.  Hence the result of our present study shows that the 
expression of mTOR plays a vital role in this signaling pathway of 
different grades of OSCC.  
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 In our current study, on comparing the intensity of staining in 
between OSCC and normal buccal mucosa, the intensity of staining was 
found to be statistically significant across these groups (p value =  
0.003) (Table 2 and Graph 2). These results were consistent with the 
study of Wang Di et al . ,  Clark Cheryl et al . ,  Sahin et al . ,  & Xiao et 
al .  
 
 Wang Di et al .,  (2011)  investigated the clinical signif icance of 
m-TOR and p-mTOR protein expression in human Colorectal  
Carcinomas. They obtained significant over expression of p -mTOR in 
Colorectal Adenocarcinomas than in normal mucosa samples.  This is in 
accordance with our study, where significant expressio n of p-mTOR 
was found in OSCC when compared to normal mucosa  (p=o0.007).They 
concluded that mTOR is highly associated with colorectal cancer and 
plays a key role in tumour carcinogenesis
3 7
.
 
 
 Clark Cheryl et al . ,  (2010)  evaluated the expression of p -mTOR 
and p-4EBP1 (translational factor) in Head & Neck Squamous Cell 
Carcinoma (HNSCC) samples and non-cancer mucosa samples. The 
results of their study indicated that  higher expression seen in basal 
layer of cancer samples than in non -cancer oral mucosa samples 
(p=0.001).  They concluded that m -TOR is dysregulated in HNSCC 
samples. The results of the current study were consistent with this 
study
3 3
.
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 Sahin et al.,  (2004)  evaluated mTOR in primary Liver neoplasms 
and correlated their expression with clinicopatholo gical parameters. 
Increased p-mTOR expression was seen in 15% of hepatocellular 
carcinoma (p=0.018). He concluded that the mTOR signaling pathway 
is known to be upregulated in various carcinoma including human 
Ovarian and Breast Carcinomas. Protein transla tion is highly regulated 
in cells, in part by the mTOR pathway, which provides nutrient and 
energy availability and phosphorylates p70S6 kinase (S6k) to promote 
protein translation. S6k in turn phosphorylates the 40s ribosomal 
subunit of protein S6 which leads to increased translation of mRNAs 
containing 5’-terminal oligopyrimidine tracts which code for ribosomal 
proteins and elongation factors which is necessary for protein 
translation. Thus, the mTOR pathway is an attractive target for cancer 
therapeutics as effective target for cancer therapeutics, as effective 
mTOR inhibitors such as Rapamycin block mTOR phosphorylation of 
S6k
5 1
.
 
 
 Xiao et al.,  (2009) analysed the role of mTOR and p70S6k in 
pathogenesis and progression of gastric carcinomas. They found t hat 
expression of p-mTOR is high in gastric carcinoma (p<0.05). He 
concluded that mTOR plays a key role in cellular growth and 
homeostasis and its regulation is freely altered in tumours
5 2
.
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 In our study, on evaluating and comparing the area of staining  of 
p-mTOR in different grades of OSCC, the area of staining was found to 
be statistically significant between the different grades of OSCC (p 
value =0.03) (Table 3 & Graph 3). These results were consistent with 
the study conducted by Stelloo et al . ,  and Afonso Julieta et al .  
 
 On comparing the area of staining, out of 7 cases of Well  
differentiated OSCC,5 cases (71%) showed posit ive stained cells.  Out 
of 7 cases of Moderately differentiated OSCCs, 3 cases (42%) showed 
positive stained cells. Out of 7 cases  of Poorly differentiated SCCs 
none of the cases showed posit ive stained cells.  
 
 Stelloo et al.,  (2015)  assessed the mTOR pathway activation in 
human Prostate Adenocarcinoma. They correlated the expression of 
mTOR with clinical parameters. Low mTOR expres sion (based on 
positive % of tumour cells) is associated with high pathologic stage  
(p=0.01).  The results of our study are consistent with the study of 
Stelloo et al  
5 3
.  
 
 Afonso Julieta et al . ,  (2014)  investigated the p- mTOR in non - 
tumour and tumour bladder urothelium. The results of their study are,  
the expression of p-mTOR decreased with increasing stage (based on 
both intensity of staining and % of positive tumour cells) and the 
mTOR expression was lost with enhanced tumour aggressiveness 
(p=0.087).  The results of the present study are consistent with the 
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study of Afonso Julieta et al  as we obtained negative stain for Poorly 
differentiated SCCs
5 4
.  
 
 In our study, on comparing the area of staining in between OSCC 
and normal buccal mucosa, the area of s taining was found to be 
statistically significant across these groups (p value =0.003) (Table 4 
and Graph 4).  These results were consistent with the study of Altomare 
et al . ,  and Min Li et al.  
 
 Altomare et al.,  (2004)  evaluated Akt and mTOR 
phosphorylation in Ovarian cancers. In  their study 87% of Ovarian 
Cancers are associated with active mTOR expression. He concluded 
that activation of PI3/Akt pathway contribute to tumorigenesis  
(p=0.03). The results of our study are consistent with this study
5 5
.  
 
 Min Li et al .,  (2012)  evaluated the Immunohistochemical 
expression of mTOR and PTEN in gastric carcinoma and in normal 
mucosa. They found that the mTOR was distributed mainly in the 
cytoplasm of Gastric Carcinoma tissues (based on both intensity of 
staining and % of positive tumour cells) and the normal mucosa showed 
negative results  (p<0.01). The results of our present study are 
consistent with this study 
2 7
.  
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 We analysed the expression of p -mTOR as the first attempt in 
between different grades of OSCC and compared the expression with 
normal mucosa. Our study is a small  initiative to find out the 
significance of p-mTOR expression in different grades of OSCC.  
 
 Earlier studies have shown that  the expression of p -mTOR only 
in Breast Carcinoma, Small  Cell Lung Cancer, Oesophageal 
Carcinomas, Cervical carcinomas, Gastric Carcinomas & Colorectal  
Carcinomas. But our present study reveals the significant expression of 
p-mTOR in Akt /mTOR/pS6 signaling pathway which act as a 
prognostic marker or target for molecular t herapies.  
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SUMMARY AND CONCLUSION  
 
                         
 The aim of this study was to analyse the Immunohistochemical 
expression of p-mTOR in biopsy samples of different grades of OSCC 
in comparison with normal mucosa .A total of 31 samples, out of which 
21 cases of OSCC and 10 cases of normal buccal mucosa were taken 
from archival blocks. Immunohistochemical expression of p -mTOR 
were studied by analysis of intensity of staining and area of staining.  
 
From the present study done with anti -p-mTOR, following conclus ions 
were drawn:  
 On comparing the intensity of staining between different grades 
of OSCC the value is  statistically significant (p=0.03)  
 Statist ically significant difference (p=0.003) exists for intensity 
of staining in between OSCC and normal mucosa.  
 On comparing the area of staining between different grades of 
OSCC the value is  statistically significant (p=0.03).  
 Statist ically significant difference (p=0.003) exists for area of 
staining in between OSCC and normal mucosa.  
 
 Our present study reveals the significant expression of p -mTOR 
in Akt /mTOR/pS6 signaling pathway which act as a prognostic marker 
or target for molecular therapies. Further research with a larger number 
of sample size with clinicopathologic correlation and long term follow 
up will emphasize more towards the use of mTOR as a prognostic 
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marker. It will also be more interesting to correlate the presence and 
frequency of other molecular aberrations such as  p-Akt and pS6 to 
trace out the role of entire Akt /mTOR/pS6 signaling pat hway in OSCC 
which will also be useful for the development  of new therapeutic 
strategies targeting on mTOR pathway.  
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